NEW YORK -- Pharmaceutical startup Insilico Medicine has begun Phase 2 clinical trials of the world's first drug candidate of its kind to be discovered and designed using generative artificial intelligence.
The trial involves 60 patients with idiopathic pulmonary fibrosis (IPF) at around 40 sites in the U.S. and China, the New York- and Hong Kong-headquartered company said Tuesday.
%2520%E3%81%AE%E3%82%B3%E3%83%94%E3%83%BC.jpg?width=700&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=394)
